SBI, Theragnostics ink oral cancer technology deal

By AuntMinnie.com staff writers

September 23, 2020 -- Molecular radiotherapy developer Theragnostics and Summit Biomedical Imaging (SBI) have signed a licensing agreement to support the development of SBI's oral cancer detection technology.

The technology is intended to provide earlier diagnosis of cancer using the poly (ADP-ribose) polymerase (PARP) inhibitor PARPi-FL and fluorescence imaging in the oral cavity.

PARP activity and expression are upregulated in tumor cells. The inhibitor binds to PARP with a fluorescence tag, bringing the optical imaging agent to the cancer and enabling direct tumor detection, according to the companies.


Copyright © 2020 AuntMinnie.com
 

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking
account: